Loading company…
San Francisco biotech developing neuroprotective medicines for Alzheimer's, multiple sclerosis and ALS.
Founded in 2018 and headquartered in San Francisco, US, Nura Bio Inc. develops neuroprotective medicines that target axon degeneration and neuroimmune regulation in neurological diseases such as Alzheimer's disease, multiple sclerosis and amyotrophic lateral sclerosis. The company is led by CEO Alpna Seth. In June 2026 it raised USD 73.8 million in Series B funding led by The Column Group, with participation from Euclidean Capital, Samsara BioCapital and Sanofi Ventures, to advance clinical studies.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in